文献速递肝病消化道肿瘤与早癌

OGDHL沉默通过重编程谷氨酰胺代谢促进肝细胞癌

OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
PubMed 文献 · J Hepatol · 2019-12-30

该研究探讨OGDHL在肝细胞癌脂质代谢调控中的作用,发现OGDHL低表达与晚期肿瘤、更差生存和更频繁复发相关,机制上OGDHL下调通过降低OGDHC活性升高αKG:柠檬酸比值,驱动谷氨酰胺还原性羧化,激活mTORC1促进脂质合成,并增强抗氧化系统,抑制OGDHL或使用谷氨酰胺酶抑制剂可增敏索拉非尼。

要点

  • OGDHL低表达与肝癌晚期、更差生存和更频繁复发相关。
  • OGDHL沉默通过升高αKG:柠檬酸比值重编程谷氨酰胺代谢促进脂质合成。
  • 抑制OGDHL或谷氨酰胺酶可增敏索拉非尼。

核心结论

  • OGDHL沉默通过调控谷氨酰胺代谢途径促进肝细胞癌发展和生存,是有前景的预后生物标志物和治疗靶点。

研究设计与样本

  • 研究系统探究OGDHL在肝癌细胞和小鼠异种移植模型中对脂质代谢的调控作用,并在3个独立队列共681例术后HCC患者中分析其临床相关性。

主要发现

  • 在3个独立队列共681例术后HCC患者中,OGDHL低表达与晚期肿瘤分期、显著更差生存和更频繁肿瘤复发相关。
  • 启动子高甲基化和DNA拷贝缺失独立与HCC标本中OGDHL表达降低相关。
  • OGDHL过表达显著抑制小鼠异种移植中肝癌细胞生长,而OGDHL敲低促进肝癌细胞增殖。
  • 机制上,OGDHL下调通过降低OGDHC活性升高αKG:柠檬酸比值,驱动谷氨酰胺来源αKG经逆行三羧酸循环的还原性羧化。
  • OGDHL沉默以αKG依赖方式激活mTORC1信号,诱导从头脂质合成关键酶转录,并提供NADPH和谷胱甘肽支持抗氧化系统。

临床怎么用

  • OGDHL低表达可能作为HCC预后生物标志物,用于识别生存更差和复发风险更高的患者。
  • 在OGDHL阴性肝癌中,减少还原性谷氨酰胺代谢(如OGDHL过表达或谷氨酰胺酶抑制剂)可能增敏索拉非尼。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mitochondrial dysfunction and subsequent metabolic deregulation are commonly observed in cancers, including hepatocellular carcinoma (HCC). When mitochondrial function is impaired, reductive glutamine metabolism is a major cellular carbon source for de novo lipogenesis to support cancer cell growth. The underlying regulators of reductively metabolized glutamine in mitochondrial dysfunction are not completely understood in tumorigenesis. METHODS: We systematically investigated the role of oxoglutarate dehydrogenase-like (OGDHL), one of the rate-limiting components of the key mitochondrial multi-enzyme OGDH complex (OGDHC), in the regulation of lipid metabolism in hepatoma cells and mouse xenograft models. RESULTS: Lower expression of OGDHL was associated with advanced tumor stage, significantly worse survival and more frequent tumor recurrence in 3 independent cohorts totaling 681 postoperative HCC patients. Promoter hypermethylation and DNA copy deletion of OGDHL were independently correlated with reduced OGDHL expression in HCC specimens. Additionally, OGDHL overexpression significantly inhibited the growth of hepatoma cells in mouse xenografts, while knockdown of OGDHL promoted proliferation of hepatoma cells. Mechanistically, OGDHL downregulation upregulated the α-ketoglutarate (αKG):citrate ratio by reducing OGDHC activity, which subsequently drove reductive carboxylation of glutamine-derived αKG via retrograde tricarboxylic acid cycling in hepatoma cells. Notably, silencing of OGDHL activated the mTORC1 signaling pathway in an αKG-dependent manner, inducing transcription of enzymes with key roles in de novo lipogenesis. Meanwhile, metabolic reprogramming in OGDHL-negative hepatoma cells provided an abundant supply of NADPH and glutathione to support the cellular antioxidant system. The reduction of reductive glutamine metabolism through OGDHL overexpression or glutaminase inhibitors sensitized tumor cells to sorafenib, a molecular-targeted therapy for HCC. CONCLUSION: Our findings established that silencing of OGDHL contributed to HCC development and survival by regulating glutamine metabolic pathways. OGDHL is a promising prognostic biomarker and therapeutic target for HCC. LAY SUMMARY: Hepatocellular carcinoma (HCC) is one of the most prevalent tumors worldwide and is correlated with a high mortality rate. In patients with HCC, lower expression of the enzyme OGDHL is significantly associated with worse survival. Herein, we show that silencing of OGDHL induces lipogenesis and influences the chemosensitization effect of sorafenib in liver cancer cells by reprogramming glutamine metabolism. OGDHL is a promising prognostic biomarker and potential therapeutic target in OGDHL-negative liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dai W, Xu L, Yu X, et al. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J Hepatol. 2019. PMID: 31899205. doi:10.1016/j.jhep.2019.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。